Porton Pharma Solutions Ltd.

300363

CNE100001S57

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
16.98 ^CNY	+2.10%		+5.14%	-32.49%

Apr. 26	Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Porton Pharma Solutions Ltd.(XSEC:300363) added to S&P Global BMI Index

September 19, 2022 at 12:00 am EDT

Latest news about Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	Apr. 09	CI
Porton Pharma Solutions Ltd.'s Equity Buyback announced on October 28, 2023, has closed with 1,260,000 shares, representing 0.23% for CNY 29.87 million.	Apr. 08	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	Apr. 03	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	Jan. 03	CI
Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 30 million worth of its shares.	23-10-27	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Porton Pharma Solutions Ltd. authorizes a Buyback Plan.	23-10-26	CI
Porton Pharma Solutions Ltd. agreed to acquire 30% stake in Hubei Yuyang Pharmaceutical Co., Ltd. for CNY73.5 million.	23-09-14	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Porton Pharma Solutions Ltd. Announces Final Dividend for the Year 2022, Payable on 09 May 2023	23-04-28	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Porton Pharma Solutions Ltd. Approves Cash Dividend for the Year 2022	23-04-18	CI
Porton Pharma Sees Up to 25% Profit Drop in Q1 on Lower Orders	23-04-03	MT
Porton Pharma Solutions Ltd. Proposes Profit Distribution for 2022	23-03-27	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Porton Pharma to Build 2.5 Billion Yuan Drug R&D, Production Facility	23-01-20	MT
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022.	22-11-22	CI
Porton Pharma Solutions Ltd.'s Equity Buyback announced on August 4, 2022, has closed with 2,022,344 shares, representing 0.37% for CNY 100 million.	22-11-20	CI
Shanghai Feiteng Pharmaceutical Technology Co., Ltd. announced that it has received CNY 60 million in funding from Porton Pharma Solutions Ltd.	22-10-26	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022.	22-10-10	CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to S&P Global BMI Index	22-09-19	CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to FTSE All-World Index	22-09-19	CI

Chart Porton Pharma Solutions Ltd.

Duration

Period

More charts

Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Porton Pharma Solutions Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.98 CNY

Average target price

28.5 CNY

Spread / Average Target

+67.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PORTON PHARMA SOLUTIONS LTD.	-32.49%	1.28B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals